Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.

MNK

Mallinckrodt (MNK)

Mallinckrodt Plc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NYSE:MNK
FechaHoraFuenteTítuloSímboloCompañía
09/05/202405:45PR Newswire (US)Mallinckrodt plc Reports First Quarter 2024 Financial Results and Reaffirms Full Year GuidanceNYSE:MNKMallinckrodt Plc
26/03/202415:01PR Newswire (US)Mallinckrodt plc Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides 2024 GuidanceNYSE:MNKMallinckrodt Plc
11/03/202405:52PR Newswire (US)Mallinckrodt Announces Journal Publication of Real-World Data on Acthar® Gel (repository corticotropin injection) to Treat Symptomatic Sarcoidosis in African American and Non-African American PatientsNYSE:MNKMallinckrodt Plc
04/03/202405:45PR Newswire (US)Mallinckrodt Announces Appointment of Paul O'Neill as Executive Vice President, Quality & Operations, Specialty BrandsNYSE:MNKMallinckrodt Plc
01/03/202407:50PR Newswire (US)Mallinckrodt Announces U.S. FDA Approval of Supplemental New Drug Application for Acthar® Gel (repository corticotropin injection) Single-Dose Pre-filled SelfJect™ InjectorNYSE:MNKMallinckrodt Plc
02/02/202407:45PR Newswire (US)Mallinckrodt Announces Board of Directors and Leadership UpdatesNYSE:MNKMallinckrodt Plc
22/01/202405:52PR Newswire (US)Mallinckrodt Presents New Data on TERLIVAZ® (terlipressin) for Injection at the Society of Critical Care Medicine (SCCM) 2024 Critical Care CongressNYSE:MNKMallinckrodt Plc
01/11/202305:45PR Newswire (US)Mallinckrodt to Present Data on TERLIVAZ® (terlipressin) for Injection in Adult Patients with Hepatorenal Syndrome (HRS) at the American Society of Nephrology (ASN) Kidney Week 2023 Scientific MeetingNYSE:MNKMallinckrodt Plc
26/10/202305:53PR Newswire (US)Mallinckrodt Presents Latest Health Economics Data on Acthar® Gel (Repository Corticotropin Injection) at the Academy of Managed Care Pharmacy (AMCP) Nexus 2023NYSE:MNKMallinckrodt Plc
30/08/202310:54PR Newswire (US)Mallinckrodt Receives Court Approval for "First Day" Motions to Support Ongoing OperationsNYSE:MNKMallinckrodt Plc
29/06/202317:53Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NYSE:MNKMallinckrodt Plc
26/06/202305:48Edgar (US Regulatory)Current Report Filing (8-k)NYSE:MNKMallinckrodt Plc
23/06/202315:43Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NYSE:MNKMallinckrodt Plc
16/06/202316:05Edgar (US Regulatory)Statement of Beneficial Ownership (sc 13d)NYSE:MNKMallinckrodt Plc
31/05/202315:07Edgar (US Regulatory)Specialized Disclosure Report (sd)NYSE:MNKMallinckrodt Plc
30/05/202315:32Edgar (US Regulatory)Statement of Ownership (sc 13g)NYSE:MNKMallinckrodt Plc
09/05/202305:52Edgar (US Regulatory)Quarterly Report (10-q)NYSE:MNKMallinckrodt Plc
05/04/202315:34Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NYSE:MNKMallinckrodt Plc
05/04/202315:32Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NYSE:MNKMallinckrodt Plc
22/01/202313:00PR Newswire (US)Mallinckrodt Presents New TERLIVAZ® (terlipressin) for Injection Data on Hepatorenal Syndrome (HRS) Reversal at the Society of Critical Care Medicine (SCCM) 2023 Critical Care CongressNYSE:MNKMallinckrodt Plc
12/01/202305:45PR Newswire (US)Mallinckrodt Announces Appointment of Dr. Peter Richardson, MRCP, as Chief Scientific OfficerNYSE:MNKMallinckrodt Plc
16/11/202205:52PR Newswire (US)Mallinckrodt Announces 2022 Advancing Extracorporeal Photopheresis Immunomodulation Investigator AwardNYSE:MNKMallinckrodt Plc
08/11/202205:45PR Newswire (US)Mallinckrodt plc Reports Third Quarter 2022 Financial Results and Reaffirms GuidanceNYSE:MNKMallinckrodt Plc
03/11/202205:53PR Newswire (US)Mallinckrodt to Present Data on TERLIVAZ® (terlipressin) for Injection in Adult Patients with Hepatorenal Syndrome (HRS) at the American Association for the Study of Liver Diseases (AASLD) 2022 Liver MeetingNYSE:MNKMallinckrodt Plc
01/11/202205:53PR Newswire (US)Mallinckrodt to Present Data on TERLIVAZ® (terlipressin) for Injection in Adult Patients with Hepatorenal Syndrome (HRS) at the American Society of Nephrology (ASN) Kidney Week 2022 Scientific MeetingNYSE:MNKMallinckrodt Plc
24/10/202209:07Edgar (US Regulatory)Certification by the Exchange Approving Securities for Listing (cert)NYSE:MNKMallinckrodt Plc
24/10/202206:25Edgar (US Regulatory)Securities Registration (section 12(b)) (8-a12b)NYSE:MNKMallinckrodt Plc
24/10/202205:45PR Newswire (US)Mallinckrodt Receives Approval to List on NYSE AmericanNYSE:MNKMallinckrodt Plc
12/10/202215:49Edgar (US Regulatory)Amended Current Report Filing (8-k/a)NYSE:MNKMallinckrodt Plc
06/10/202205:45PR Newswire (US)Mallinckrodt Announces Appointment of Susan Silbermann to its Board of DirectorsNYSE:MNKMallinckrodt Plc
 Showing the most relevant articles for your search:NYSE:MNK